Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ADIL · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Parti… NCT07888569 · Healthy DZD8586, Rabeprazole | AZR Dizal Pharmaceuticals | Phase 1 | Recruiting was not yet recruiting | 26 | Nov 23, 2026 | Registry ↗ |
| Oct 29, 2026 | A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-s… NCT05668988 · Non-small Cell Lung Cancer sunvozertinib, Pemetrexed+carboplatin | AZR Dizal Pharmaceuticals | Phase 3 | Active, not recruiting | 324 | Jan 16, 2026 | Registry ↗ |
| Oct 23, 2026 | Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCL… NCT07079475 · Non-Small Cell Lung Cancer DZD6008, Sunvozertinib | AZR Dizal Pharmaceuticals | Phase 1/2 | Recruiting | 220 | Jun 2028 | Registry ↗ |
| Oct 23, 2026 | A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC… NCT06905197 · Non Small Cell Lung Cancer DZD6008, Sunvozertinib | AZR Dizal Pharmaceuticals | Phase 1 | Recruiting | 140 | Sep 2027 | Registry ↗ |
| Oct 22, 2026 | Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) NCT07496229 · T-cell Lymphomas GW5282 combined with Golidocitinib, GW5282 combined with Go… | AZR Dizal Pharmaceuticals | Phase 1/2 | Recruiting | 220 | Sep 2029 | Registry ↗ |
| Oct 22, 2026 | A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC… NCT06295432 · Non-small Cell Lung Cancer DZD9008+AZD4205 | AZR Dizal Pharmaceuticals | Phase 2 | Completed | 30 | Jun 8, 2026 | Registry ↗ |
| Aug 31, 2026 | DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutatio… NCT07070440 · Non Small Cell Lung Cancer DZD6008, Pemetrexed | AZR Dizal Pharmaceuticals | Phase 1/2 | Recruiting | 180 | Jun 2027 | Registry ↗ |
| Aug 28, 2026 | Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (… NCT06813365 · Nonsmall-cell Lung Cancer DZD6008 | AZR Dizal Pharmaceuticals | Phase 1 | Recruiting | 300 | Oct 30, 2027 | Registry ↗ |
| Aug 5, 2026 | Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) NCT07712588 · Diffuse Large B-Cell Lymphoma (DLBCL) Birelentinib, Rituximab | AZR Dizal Pharmaceuticals | Phase 2/3 | Not yet recruiting | 880 | Jan 2031 | Registry ↗ |
| Aug 4, 2026 | DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) NCT06539195 · Diffuse Large B Cell Lymphoma DZD8586, DZD8586 | AZR Dizal Pharmaceuticals | Phase 2 | Completed | 59 | Jun 10, 2026 | Registry ↗ |
| Jul 2, 2026 | DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT05824585 · Lymphoma, Non-Hodgkin DZD8586 | AZR Dizal Pharmaceuticals | Phase 1 | Completed | 17 | Jun 30, 2025 | Registry ↗ |
| Jun 22, 2026 | A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) NCT07154264 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma DZD8586, Venetoclax | AZR Dizal Pharmaceuticals | Phase 2 | Recruiting | 66 | Dec 2029 | Registry ↗ |
| Jun 8, 2026 | A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) NCT07234162 · Peripheral T-cell Lymphoma Golidocitinib, Chidamide | AZR Dizal Pharmaceuticals | Phase 3 | Recruiting | 218 | Nov 30, 2027 | Registry ↗ |
| Jun 3, 2026 | A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) NCT07139873 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma DZD8586, Bendamustine | AZR Dizal Pharmaceuticals | Phase 3 | Recruiting | 250 | Jan 2029 | Registry ↗ |
| Jun 2, 2026 | DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) NCT06539182 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma DZD8586, DZD8586 | AZR Dizal Pharmaceuticals | Phase 2 | Recruiting | 155 | Sep 2027 | Registry ↗ |
| May 14, 2026 | A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15) NCT07454863 · Lymphoma, Non-Hodgkin DZD8586 | AZR Dizal Pharmaceuticals | Phase 1 | Completed | 6 | Mar 27, 2026 | Registry ↗ |
| Apr 1, 2026 | DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) NCT07059650 · Diffuse Large B-Cell Lymphoma DZD8586+R-CHOP, DZD8586+R-GemOx | AZR Dizal Pharmaceuticals | Phase 1/2 | Recruiting | 150 | Oct 2030 | Registry ↗ |
| Feb 11, 2026 | A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors NCT07328217 · Advanced Solid Tumors GW5282, GW5282 | AZR Dizal Pharmaceuticals | Phase 1/2 | Recruiting | 203 | Dec 2028 | Registry ↗ |
| Jan 29, 2026 | Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung C… NCT03974022 · Non-Small Cell Lung Cancer Sunvozertinib | AZR Dizal Pharmaceuticals | Phase 1/2 | Active, not recruiting | 315 | Jul 29, 2024 | Registry ↗ |
| Jan 22, 2026 | A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) NCT07294365 · Immune Thrombocytopenia (ITP) DZD8586 dose level 1, DZD8586 dose level 2 | AZR Dizal Pharmaceuticals | Phase 2 | Recruiting | 60 | Jul 2027 | Registry ↗ |
| Dec 24, 2025 | AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) NCT06511895 · Peripheral T Cell Lymphoma AZD4205 | AZR Dizal Pharmaceuticals | Phase 2 | Completed | 57 | Oct 17, 2025 | Registry ↗ |
| Jul 4, 2025 | AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) NCT06511869 · Peripheral T-cell Lymphoma AZD4205 | AZR Dizal Pharmaceuticals | Phase 2 | Completed | 48 | Mar 31, 2025 | Registry ↗ |
| Jun 19, 2025 | DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR… NCT06276283 · Non-small Cell Lung Cancer DZD9008 plus Bevacizumab | AZR Dizal Pharmaceuticals | Phase 2 | Recruiting | 60 | Dec 31, 2025 | Registry ↗ |
| Apr 4, 2025 | Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT… NCT04105010 · Relapsed or Refractory Peripheral T Cell Lymphoma golidocitinib | AZR Dizal Pharmaceuticals | Phase 1/2 | Completed | 171 | Oct 12, 2023 | Registry ↗ |
| Apr 1, 2025 | DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients… NCT04509596 · Breast Cancer Metastatic DZD1516 mono therapy in Part A, DZD1516 in combination with… | AZR Dizal Pharmaceuticals | Phase 1 | Completed | 23 | Jul 7, 2022 | Registry ↗ |
| Feb 25, 2025 | Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell… NCT04148742 · Non-Hodgkin's B-cell Lymphoma DZD9008 | AZR Dizal Pharmaceuticals | Phase 1/2 | Withdrawn | 0 | Jul 2023 | Registry ↗ |
| Feb 21, 2025 | A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) NCT05844956 · Lymphoma, Non-Hodgkin DZD8586 | AZR Dizal Pharmaceuticals | Phase 1/2 | Completed | 17 | Feb 29, 2024 | Registry ↗ |
| Dec 30, 2024 | Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-… NCT05712902 · Non-Small Cell Lung Cancer Sunvozertinib | AZR Dizal Pharmaceuticals | Phase 2 | Active, not recruiting | 104 | Oct 17, 2022 | Registry ↗ |
| Dec 18, 2024 | DZD9008 PK Study in Hepatic Impairment Subjects NCT06084104 · Hepatic Impairment DZD9008, DZD9008 | AZR Dizal Pharmaceuticals | Phase 1 | Completed | 17 | Jun 12, 2024 | Registry ↗ |
| Dec 13, 2024 | Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for C… NCT05926180 · Non-small Cell Lung Cancer DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin) | AZR Dizal Pharmaceuticals | Phase 1 | Completed | 25 | May 16, 2024 | Registry ↗ |
| Apr 17, 2024 | Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter… NCT04101227 · Alcohol Use Disorder AD04 (ondansetron), Matching placebo | AZR Adial Pharmaceuticals | Phase 3 | Completed | 302 | Feb 18, 2022 | Registry ↗ |
| Jun 23, 2023 | Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine NCT05418582 · Healthy Subjects DZD9008 and intraconazole, DZD9008 and carbamazepine | AZR Dizal Pharmaceuticals | Phase 1 | Completed | 40 | Jun 1, 2022 | Registry ↗ |
| Feb 1, 2023 | Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine NCT05486949 · Healthy Subjects AZD4205 and carbamazepine, AZD4205 and itraconazole | AZR Dizal Pharmaceuticals | Phase 1 | Completed | 32 | Oct 8, 2022 | Registry ↗ |
| Jul 11, 2022 | Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC NCT04634344 · Metastatic Castration Resistant Prostate Cancer DZD2269 | AZR Dizal Pharmaceuticals | Phase 1 | Terminated | 16 | May 5, 2022 | Registry ↗ |
| Jul 1, 2022 | A Study of DZD2269 in Healthy Adult Participants NCT04932005 · Healthy Volunteers DZD2269, placebo | AZR Dizal Pharmaceuticals | Phase 1 | Completed | 72 | Apr 1, 2022 | Registry ↗ |
| Jun 2, 2022 | Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Me… NCT04909242 · Healthy Volunteers DZD9008, Placebo | AZR Dizal Pharmaceuticals | Phase 1 | Completed | 78 | Feb 7, 2022 | Registry ↗ |
| May 25, 2022 | Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects NCT05159895 · Healthy Volunteers [14C]-DZD9008 | AZR Dizal Pharmaceuticals | Phase 1 | Completed | 8 | Mar 30, 2022 | Registry ↗ |
| Aug 24, 2020 | Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male V… NCT04225208 · Healthy Volunteers [14C]-AZD4205, single 50 mg oral dose administrated on day 1 | AZR Dizal Pharmaceuticals | Phase 1 | Completed | 8 | Mar 2, 2020 | Registry ↗ |
| Aug 24, 2020 | A Study of AZD4205 in Healthy Adult Subjects NCT03728023 · Healthy Volunteers AZD4205, Placebo | AZR Dizal Pharmaceuticals | Phase 1 | Completed | 66 | Aug 20, 2019 | Registry ↗ |
| Aug 24, 2020 | Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who… NCT03450330 · Nonsmall Cell Lung Cancer AZD4205 | AZR Dizal Pharmaceuticals | Phase 1/2 | Completed | 10 | Sep 3, 2019 | Registry ↗ |
40 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 5:59 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances